Slim A, Arrouti Z, Ben Redteb S; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 1004 (abstract no. 60013).
Hopital Charles Nicole, Tunis, Tunisia.
OBJECTIVES: To detect rapidly (before seroconversion or Igm response) CMV DNA in patients at risk for CMV primoinfection or reactivation. PATIENTS: 60 patients: 20 after renal transplant, 30 after medullar transplant and 10 HIV-1 presenting symptoms of opportunistic infection for CMV (3 retinitis, 4 pulmonary, 3 hepatitis) were included in the study. METHOD: Quantitative DNA assay was performed using Murex Hybrid DNA capture system. Results are exprimed in pg/ml or in CMV genomes/assay. RESULTS: For the 20 renal transplanted and the 30 medullar transplanted, CMV DNA was detected at various titer early before IgG seroconversion or Igm positivity. Therapy with Ganciclovir in these cases resulted successful. For the 10 HIV cases, CMV DNA was positive and helped medical diagnosis. CONCLUSION: Quantitative DNA assay for CMV (Murex) is a reliable, sensitive, and specific test for early detection of primoinfection or viral reactivation in immunocompromised patient Sequential samples tested during ganciclovir therapy showed decrease in CMV DNA suggesting that we can use it also for monitoring of this frequent infection in Tunisia.
Publication Types:
Keywords:
- Cytomegalovirus
- Cytomegalovirus Infections
- DNA
- DNA, Viral
- Ganciclovir
- Humans
- Immunocompromised Host
- Kidney Transplantation
- Tunisia
- immunology
- surgery
- transplantation
Other ID:
UI: 102231965
From Meeting Abstracts